Starten Sie Ihre Suche...


Wir weisen darauf hin, dass wir technisch notwendige Cookies verwenden. Weitere Informationen
Publikationen
Ergebnisse pro Seite:  10

Stintzing, S.; Miller-Phillips, L.; Modest, D. P. et al.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study

EUROPEAN JOURNAL OF CANCER. Bd. 79. 2017 S. 50-60


Baumeister, Philipp; Rauch, Josepha; Jacobi, Christian et al.

Impact of comorbidity and anemia in patients with oropharyngeal cancer primarily treated with surgery in the human papillomavirus era

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. Bd. 39. H. 1. 2017 S. 7-16


Herzer, K.; Gerken, G.; Kroy, D. et al.

IMPACT OF DIRECT-ACTING ANTIVIRAL THERAPY ON THE NEED FOR LIVER TRANSPLANTATION RELATED TO HEPATITIS C IN GERMANY

TRANSPLANT INTERNATIONAL. Bd. 30. 2017 S. 18-18


Herzer, Kerstin; Gerken, Guido; Kroy, Daniela et al.

Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany

HEPATOLOGY. Bd. 66. 2017 S. 877A-877A



Harmatz, Paul R.; Mengel, Eugen; Geberhiwot, Tarekegn et al.

Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study

AMERICAN JOURNAL OF MEDICAL GENETICS PART A. Bd. 173. H. 2. 2017 S. 375-383


Keller, Karsten; Stelzer, Kathrin; Ostad, Mir Abolfazl et al.

Impact of exaggerated blood pressure response in normotensive individuals on future hypertension and prognosis: Systematic review according to PRISMA guideline

ADVANCES IN MEDICAL SCIENCES. Bd. 62. H. 2. 2017 S. 317-329


Lenders, M.; Oder, D.; Nowak, A. et al.

Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease

JOURNAL OF INTERNAL MEDICINE. Bd. 282. H. 3. 2017 S. 241-253


Labenz, Christian; Prenosil, Vera; Koch, Sandra et al.

Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib

DIGESTIVE DISEASES. Bd. 36. H. 1. 2017 S. 78-88